Cancer Genetics, Roche Expand Agreement
News Feb 11, 2014
Under the terms of the three-year contract agreement, CGI will leverage the power of Roche's FDA-approved cobas® platform as the Company seeks to become a center of excellence for oncology-focused testing in the region. Roche's cobas® technology allows for the amplification and sequencing of targeted genomic regions of interest, using mutational status to guide appropriate treatment selection.
"When we began our relationship with Cancer Genetics, we were looking for a provider that would guarantee us the quality of the test, since that directly impacts patient care and outcome. For our patients every minute is crucial and we also wanted the focus on quality to be accompanied by excellent response and turnaround times. Over the past two years of the relationship, Cancer Genetics has continually demonstrated their commitment to both our quality requirements and response time needs. These shared values with Roche are proof that they understand the importance of getting treatment and solutions to our patients. Since day one, Cancer Genetics, has been a true business partner," said Alvaro Soto, CEO of Roche Services.
Additionally, under the agreement, CGI will be the exclusive provider of molecular diagnostic cancer testing for Roche Servicios in Central America and the Caribbean. This expanded relationship covers multiple disease categories, including testing for lung cancer, breast cancer, and lymphoma. CGI first began offering such testing for Roche Servicios in late 2012.
"The multiyear contract and expansion of our relationship with Roche Servicios is testament to the quality of the molecular diagnostic services we provide, and the focus we have on meeting clinical oncology needs," stated Panna Sharma, CEO of CGI. "Our proprietary testing solutions coupled with state-of-the-art molecular testing enables Roche Servicios to deliver personalized cancer treatment for their patients throughout the region, bringing state-of-the-art biomarker-based cancer testing into the community setting where it will have the greatest impact."
CGI will initially focus on cobas®-based testing starting with the FDA-approved epidermal growth factor receptor (EGRF) mutation test, intended to help select non-small cell lung cancer patients for treatment with EGFR inhibitors. The partnership allows for expansion into other cancer categories and regions as mutually decided by CGI and Roche.
According to the American Cancer Society, there were an estimated 255,900 new cases of cancer in Central America and the Caribbean in 2008, representing more than 2% of all cases globally. Lancet Oncology, the world's leading oncology journal, reports that while the incidence rate in the region is far lower than in the U.S. and Europe, the mortality rate is substantially higher due to late diagnosis and lack of treatment access.
Possible Biomarker to Identify Who Would Benefit from ImmunotherapyNews
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments. In a new study, researchers examined tissue samples from melanoma and ovarian cancer patients treated with immunotherapies and found a link between the percentage of antigen-presenting cells expressing PD-L1 and an objective clinical response to treatment.READ MORE
Fight Against Cancer: Drug Combination Helps Kickstart the Immune SystemNews
Scientists from King's College London have found a way to boost the immune system to help it fight back against cancer.
The breakthrough involves the first ever use of a combination of chemotherapy and a drug being trialled as a treatment for neonatal jaundice, that together help kick start the body's natural defences.
Researchers Zoom in on DNA Code Being Read in CellsNews
Scientists have unveiled incredible images of how the DNA code is read and interpreted – revealing new detail about one of the fundamental processes of life. The mechanism for reading DNA and decoding it to build proteins for their needs is common to all animals and plants, and is often hijacked by cancer. The discovery of exactly how the molecular mechanism works, could open up new approaches to cancer treatment.READ MORE